Combination product for prophylaxis and treatment of irritable bowel syndrome
AssigneePrecisionBiotics Group Limited
InventorsBarry KIELY, Eileen Frances MURPHY, David GROEGER
Life of this patent
Estimating the term…
Abstract
A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.
Claims21
1-40. (canceled)
A formulation for administration to a subject, the formulation comprising an isolated strain of Bifidobacterium deposited under accession number NCIMB 41676, an isolated strain of Bifidobacterium deposited under accession number NCIMB 41003, and an ingestible carrier.
A formulation for oral administration to a subject, the formulation comprising an isolated strain of Bifidobacterium deposited under accession number NCIMB 41676, an isolated strain of Bifidobacterium deposited under accession number NCIMB 41003, and an ingestible carrier, wherein the formulation is in the form of a capsule, a tablet, or a powder.
A formulation for oral administration to a subject, the formulation comprising a powder that comprises 108 cfu to 1010 cfu of an isolated strain of Bifidobacterium deposited under accession number NCIMB 41676 and 108 cfu to 1010 cfu of an isolated strain of Bifidobacterium deposited under accession number NCIMB 41003, the formulation further comprising an ingestible carrier.
Dependencies are inferred from the claim text.